Biology is becoming engineerable
we are investing in a future where bioengineering has industrial scale and speed, and today’s barely conceivable medicines are routine
We partner with innovators
building groundbreaking companies with the following characteristics
Life-Threatening Disease With Hard Endpoint
agnostic across all life-threatening disease wherever approvable endpoints are well-established and objective
Novel Therapeutic Platform In Any Modality
modality agnostic wherever cutting-edge discovery tools are being used to develop multiple compounds
Lead Reaching Human Proof-Of-Concept
lead candidate has human PoC or is expected to reach it with our first investment round
Designed for manufacturability
appropriate manufacturing at each stage of development with clear potential for commercial scale
Latest News
Tell us about your company
"*" indicates required fields